Sienna Biopharmaceuticals, Inc.
SNNA
SNNA was delisted on the 16th of December, 2019.
23 hedge funds and large institutions have $1.08M invested in Sienna Biopharmaceuticals, Inc. in 2019 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 13 reducing their positions, and 25 closing their positions.
52% less funds holding
Funds holding: 48 → 23 (-25)
69% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 13
91% less capital invested
Capital invested by funds: $12.3M → $1.08M (-$11.2M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$29.3K |
| 2 |
Goldman Sachs
New York
|
+$4.14K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$229 |
| 4 |
JP Morgan Chase
New York
|
+$15 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$2.25M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.62M |
| 3 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$660K |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$515K |
| 5 |
Renaissance Technologies
New York
|
-$510K |
SNNA Hedge Fund Activity: Q3 2019 in Review
23 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Sienna Biopharmaceuticals, Inc. (SNNA) for Q3 2019, worth a combined $1.08M — down 91% from $12.3M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of SNNA and 0 opened new positions — a net loss of 25 holders — while 13 trimmed existing stakes and 4 added.
The largest buyer was Citadel Advisors, adding an estimated $29.3K. The largest seller was PFM Health Sciences, exiting entirely with an estimated $2.25M sold.
- 23 institutional investors held Sienna Biopharmaceuticals, Inc. (SNNA) as of Q3 2019, down from 48 in Q2 2019.
- Funds reported $1.08M of Sienna Biopharmaceuticals, Inc. stock for Q3 2019, down 91% quarter-over-quarter.
- 0 funds opened new Sienna Biopharmaceuticals, Inc. positions in Q3 2019 and 25 closed out, a net change of -25 holders.
- The largest Sienna Biopharmaceuticals, Inc. buyer in Q3 2019 was Citadel Advisors, an estimated $29.3K added.
- The largest Sienna Biopharmaceuticals, Inc. seller in Q3 2019 was PFM Health Sciences, an estimated $2.25M sold.
Based on aggregated 13F filings for Q3 2019.